Disease · MONDO_0002113
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 20
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00316173 | Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | Phase 2 | 77 | 2009-11-26 | Ovarian Cancer, Neoplasms, Ovarian | CARBOPLATIN, TOPOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT00407563 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | Phase 2 | 48 | 2012-04-05 | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | BEVACIZUMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | Phase 2 | 36 | 2014-12-02 | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | SUNITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02834975 | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Phase 2 | 26 | 2023-11-07 | Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer | CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | Phase 2 | 20 | 2017-07-02 | Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Carcinosarcoma | BEVACIZUMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT01936974 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | Phase 2 | 7 | 2017-10-25 | Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, GEMCITABINE, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00003636 | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer | Phase 3 | 704 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | CARBOPLATIN, CISPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01837251 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | Phase 3 | 682 | Recurrent Platinum-sensitive Ovarian Cancer | BEVACIZUMAB, CARBOPLATIN, DOXORUBICIN, GEMCITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Phase 3 | 615 | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT05080946 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early phase 1 | 100 | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | ASPIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01616303 | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | Phase 2 | 97 | Ovarian Neoplasms | CARBOPLATIN, OREGOVOMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT04670978 | Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer | Phase 2 | 96 | Objective Response Rate | BEVACIZUMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | Phase 2 | 88 | Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00216645 | Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy | Phase 2 | 74 | Ovarian Neoplasms | DOXORUBICIN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01600573 | Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) | Phase 1/2 | 68 | Ovarian Cancer | PAZOPANIB, TOPOTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT04938583 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | Phase 1/2 | 54 | Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV | BEVACIZUMAB, CARBOPLATIN, OREGOVOMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00003385 | Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | Phase 1 | 48 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | CARBOPLATIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00248248 | DOXIL for Consolidation Therapy in Ovarian Cancer. | Phase 2 | 45 | Ovarian Neoplasm | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Phase 1/2 | 12 | Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma | FENRETINIDE, KETOCONAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00012090 | Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum | Phase 2 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | BICALUTAMIDE, GOSERELIN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002113/trials